Mutual of America Capital Management LLC Has $4.71 Million Stock Holdings in Cencora, Inc. (NYSE:COR)

Mutual of America Capital Management LLC decreased its stake in Cencora, Inc. (NYSE:COR) by 3.8% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 20,923 shares of the company’s stock after selling 835 shares during the quarter. Mutual of America Capital Management LLC’s holdings in Cencora were worth $4,714,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of the stock. Fisher Asset Management LLC purchased a new position in shares of Cencora in the fourth quarter worth approximately $244,000. Trust Co. of Vermont purchased a new position in Cencora during the 4th quarter worth approximately $62,000. Wahed Invest LLC acquired a new stake in Cencora during the 4th quarter valued at $567,000. Vanguard Group Inc. purchased a new stake in shares of Cencora in the fourth quarter valued at $4,212,508,000. Finally, Hennessy Advisors Inc. acquired a new stake in shares of Cencora in the fourth quarter worth $3,307,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

Cencora Stock Up 0.7 %

Cencora stock opened at $228.11 on Friday. The company has a market capitalization of $45.50 billion, a P/E ratio of 24.96, a P/E/G ratio of 1.55 and a beta of 0.44. Cencora, Inc. has a 1-year low of $178.21 and a 1-year high of $247.66. The firm’s fifty day simple moving average is $234.84 and its 200-day simple moving average is $233.11. The company has a current ratio of 0.89, a quick ratio of 0.55 and a debt-to-equity ratio of 3.93.

Cencora (NYSE:COR) last released its quarterly earnings results on Wednesday, July 31st. The company reported $3.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.18 by $0.16. Cencora had a return on equity of 266.60% and a net margin of 0.65%. The company had revenue of $74.20 billion during the quarter, compared to the consensus estimate of $73.32 billion. During the same quarter in the prior year, the company posted $2.92 EPS. The firm’s revenue was up 10.8% on a year-over-year basis. Sell-side analysts forecast that Cencora, Inc. will post 13.63 earnings per share for the current fiscal year.

Cencora Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Monday, August 26th. Stockholders of record on Friday, August 9th were given a $0.51 dividend. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date of this dividend was Friday, August 9th. Cencora’s dividend payout ratio is 22.32%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the company. JPMorgan Chase & Co. increased their price objective on Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Bank of America reissued a “neutral” rating and issued a $245.00 price target (down from $275.00) on shares of Cencora in a research report on Wednesday. Robert W. Baird lowered their price objective on shares of Cencora from $287.00 to $283.00 and set an “outperform” rating on the stock in a research report on Friday, September 6th. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the stock an “equal weight” rating in a research report on Thursday, August 1st. Finally, StockNews.com cut shares of Cencora from a “strong-buy” rating to a “buy” rating in a report on Friday. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $256.67.

Insider Transactions at Cencora

In related news, EVP Silvana Battaglia sold 1,473 shares of Cencora stock in a transaction on Tuesday, August 6th. The shares were sold at an average price of $242.69, for a total value of $357,482.37. Following the transaction, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, EVP Silvana Battaglia sold 1,473 shares of the stock in a transaction that occurred on Tuesday, August 6th. The stock was sold at an average price of $242.69, for a total transaction of $357,482.37. Following the completion of the sale, the executive vice president now owns 10,948 shares in the company, valued at approximately $2,656,970.12. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, major shareholder Walgreens Boots Alliance, Inc. sold 4,438,171 shares of Cencora stock in a transaction that occurred on Thursday, August 1st. The stock was sold at an average price of $240.56, for a total value of $1,067,646,415.76. Following the completion of the transaction, the insider now directly owns 19,980,000 shares in the company, valued at $4,806,388,800. The disclosure for this sale can be found here. Over the last three months, insiders sold 4,450,399 shares of company stock worth $1,070,392,799. 15.80% of the stock is owned by insiders.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.